R
Rodrigo Dienstmann
Researcher at Autonomous University of Barcelona
Publications - 104
Citations - 7094
Rodrigo Dienstmann is an academic researcher from Autonomous University of Barcelona. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 28, co-authored 61 publications receiving 5168 citations. Previous affiliations of Rodrigo Dienstmann include Universidade Federal do Rio Grande do Sul & Sage Bionetworks.
Papers
More filters
Journal ArticleDOI
Database of Genomic Biomarkers for Cancer Drugs and Clinical Targetability in Solid Tumors
TL;DR: The prevalence of mutations and copy-number alterations with predictive associations across solid tumors at different levels of stringency for gene-drug targetability and the challenges for treatment prioritization are illustrated.
Journal ArticleDOI
Genomic Determinants of Protein Abundance Variation in Colorectal Cancer Cells
Theodoros I. Roumeliotis,Steven P. Williams,Emanuel Gonçalves,Clara Alsinet,Martin Del Castillo Velasco-Herrera,Nanne Aben,Fatemeh Zamanzad Ghavidel,Magali Michaut,Michael Schubert,Stacey Price,James C. Wright,Lu Yu,Mi Yang,Rodrigo Dienstmann,Justin Guinney,Pedro Beltrao,Alvis Brazma,Mercedes Pardo,Oliver Stegle,David J. Adams,Lodewyk F. A. Wessels,Lodewyk F. A. Wessels,Julio Saez-Rodriguez,Julio Saez-Rodriguez,Ultan McDermott,Jyoti S. Choudhary,Jyoti S. Choudhary +26 more
TL;DR: A deep integrative view of the functional network and the molecular structure underlying the heterogeneity of colorectal cancer cells is provided.
Journal ArticleDOI
Molecular Profiling of Patients with Colorectal Cancer and Matched Targeted Therapy in Phase I Clinical Trials
Rodrigo Dienstmann,Danila Serpico,Jordi Rodon,Cristina Saura,Teresa Macarulla,Elena Elez,Maria Alsina,Jaume Capdevila,Jose Perez-Garcia,G. Sánchez-Ollé,Claudia Aura,Ludmila Prudkin,Stefania Landolfi,Javier Hernández-Losa,Ana Vivancos,Josep Tabernero +15 more
TL;DR: The results suggest that matching chemorefractory patients with colorectal cancer with targeted agents in phase I trials based on the current molecular profile does not confer a significant clinical benefit.
Journal ArticleDOI
New clinical trial designs in the era of precision medicine
Elena Garralda,Elena Garralda,Rodrigo Dienstmann,Alejandro Piris-Giménez,Irene Brana,Irene Brana,Jordi Rodon,Jordi Rodon,Josep Tabernero +8 more
TL;DR: The main challenges and opportunities that these new trial designs may provide for a more efficient drug development process, which may ultimately help ensure that PCM becomes a reality for patients are described.
Journal ArticleDOI
Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial
Clara Montagut,Guillem Argiles,Guillem Argiles,Fortunato Ciardiello,Thomas Tuxen Poulsen,Rodrigo Dienstmann,Rodrigo Dienstmann,Michael Kragh,Scott Kopetz,Trine Lindsted,C. Ding,Joana Vidal,Jenifer Clausell-Tormos,Giulia Siravegna,Francisco J. Sánchez-Martín,Klaus Koefoed,Mikkel W. Pedersen,Michael M. Grandal,Mikhail Dvorkin,Lucjan Wyrwicz,Ana Rovira,Antonio Cubillo,Ramon Salazar,Françoise Desseigne,Cristina Nadal,Joan Albanell,Vittorina Zagonel,Salvatore Siena,Guglielmo Fumi,Giuseppe Rospo,Paul Nadler,Ivan D. Horak,Alberto Bardelli,Josep Tabernero,Josep Tabernero +34 more
TL;DR: The ctDNA revealed high intrapatient genomic heterogeneity following anti-EGFR therapy, and Sym004 effectively targeted EGFR ECD-mutated cancer cells, but this did not translate into clinical benefit in patients with EGfr ECD mutations, likely owing to co-occurring resistance mechanisms.